
Sign up to save your podcasts
Or


2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:
By Breastcancer.org4.3
4242 ratings
2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:

21,941 Listeners

1,115 Listeners

2,033 Listeners

1,691 Listeners

2,637 Listeners

3,493 Listeners

9,295 Listeners

53 Listeners

4,489 Listeners

328 Listeners

388 Listeners

20,212 Listeners

1,177 Listeners

120 Listeners

30 Listeners